Plantar Fibromatosis (Ledderhose Disease): Nodules on the Arch and Treatment Options

Quick answer: Plantar Fibromatosis Ledderhose Disease Arch Nodules is a clinical condition that responds to evidence-based treatment when caught early. Symptoms include pain, swelling, and altered function. Diagnosis requires clinical exam, often imaging. Treatment ladder: conservative care first (4-6 weeks), then targeted interventions if needed. Call (810) 206-1402.

Treatment at Balance Foot & Ankle: EPAT Shockwave for Heel Pain →

Quick Answer

Plantar fibromatosis (Ledderhose disease) is a benign but slow-growing nodule in the arch of the foot, made of the same fibrous tissue as Dupuytren’s contracture in the hand. It is rarely cancerous, but the lumps can become painful and recur after surgery. Call (810) 206-1402 for a Howell or Bloomfield Hills, MI evaluation.

You felt a lump in the arch of your foot. Maybe you noticed it pressing into the floor when you walk barefoot, or you happened to run your hand across the bottom of your foot one night. The first reaction — almost universally — is to assume the worst. The reality, in our clinic, is that the overwhelming majority of these lumps are plantar fibromatosis, also called Ledderhose disease. It is benign, slow, and very treatable, and the right plan depends almost entirely on whether the lump is causing pain, growing fast, or interfering with your shoes. Here is what we tell every patient who walks in with a knot in the arch.

What is plantar fibromatosis?

Plantar fibromatosis is a benign overgrowth of the fibrous tissue that makes up the plantar fascia — the thick band of connective tissue that runs along the bottom of the foot. Instead of staying as a smooth sheet, the fascia thickens and forms a discrete nodule (or several) in the medial arch. The nodules are made of myofibroblasts — the same cell type that drives Dupuytren’s contracture in the hand and Peyronie’s disease in the penis — and the three conditions often run in the same patient and the same family. The lumps grow slowly over months to years, can stop growing on their own, and rarely transform into anything dangerous.

In our clinic, we see plantar fibromatosis in patients across a wide age range, but the median is 40–60 years old, with men slightly more affected than women. Many patients have a family member with Dupuytren’s contracture; this is one of the most reliable historical clues. Most lumps are 1–3 cm by the time we see them, and most are painless at rest but uncomfortable when standing on hard floors or walking barefoot.

Why it’s called Ledderhose disease

The condition is named for Georg Ledderhose, the 19th-century German surgeon who first described it as a discrete clinical entity. The eponym is useful because it links the foot version with its sibling conditions in the hand (Dupuytren’s) and the penis (Peyronie’s) — sometimes called the “superficial fibromatoses.” Patients who have one of the three are at higher risk for the others, and a family history of Dupuytren’s in particular makes the diagnosis of plantar fibromatosis much more likely when a foot lump appears.

Symptoms and what the nodule feels like

The classic plantar fibromatosis nodule has a distinct character on exam — firm, well-defined, fixed to the fascia, freely movable under the skin. Symptoms range from completely silent (incidental finding) to severe enough that the patient can no longer wear regular shoes. Common features include:

• A firm, marble-like nodule in the medial arch (most common location) or central plantar fascia.
• Skin tethering or dimpling over the nodule when the toes are dorsiflexed.
• Pressure-related pain when standing barefoot on hard floors or in thin-soled shoes.
• No pain at rest in most cases — pain is mechanical, not inflammatory.
• Slow size change over months — rapid growth (weeks) is not typical and warrants imaging.
• Multiple nodules in 25% of cases, in the same foot or bilaterally.
• No skin changes — the overlying skin is normal in color and temperature.

Causes, genetics, and risk factors

The exact cause of plantar fibromatosis is unknown, but several risk factors are well-documented. Genetics carry the most weight; lifestyle factors push the timing of when nodules appear.

• Family history of Dupuytren’s contracture — the strongest single predictor.
• Northern European ancestry — the so-called “Viking gene” pattern.
• Diabetes — doubles the risk; mechanism unclear.
• Alcohol use disorder — more strongly linked to Dupuytren’s but appears in plantar disease too.
• Smoking — consistent independent risk factor.
• Chronic phenytoin or barbiturate use — older anti-seizure medications.
• Repeated foot trauma — a softer association, but plausible in dancers and athletes.
• Male sex — about 2:1 male predominance.

Conditions it can be mistaken for

Several other “lumps in the foot’s arch” share clinical features with plantar fibromatosis. Telling them apart matters because the treatment paths diverge. The most common mimics include:

• Plantar fascia rupture or tear — sudden onset, swelling, often after a sprint or jump; the “lump” is hematoma or bunched fascia.
• Lipoma — soft, fatty, mobile, much more compressible than fibromatosis. Painless.
• Ganglion cyst — smoother and more fluid-feeling; transilluminates with a flashlight; arises from a tendon sheath or joint.
• Plantar epidermal cyst — superficial, often after a puncture wound; closer to the skin than the fascia.
• Schwannoma or neuroma — nerve-sheath tumors; produce shooting pain into the toes when pressed.
• Soft-tissue sarcoma (rare) — faster-growing, larger (over 5 cm), deeper, often painful at rest. Imaging mandatory.
• Foreign-body granuloma — remember the splinter or glass shard you forgot about.
• Plantar wart (verruca plantaris) — superficial, in skin, with classic black-dot appearance.

How we diagnose it

Plantar fibromatosis is primarily a clinical diagnosis — a firm, fixed, slow-growing nodule in the arch with a family history is enough in most cases. We use imaging selectively. Our standard visit:

1. Targeted history: When did you first notice it? How fast has it grown? Pain at rest or only with weight? Family history of Dupuytren’s, Peyronie’s, or knuckle pads?
2. Inspection: Any skin tethering when toes are dorsiflexed, dimples, color or temperature change?
3. Palpation: Size, firmness, mobility, fixation to fascia vs skin, transillumination, tenderness.
4. Bilateral comparison: Many patients have a small contralateral nodule they did not notice.
5. Hand exam: Look for Dupuytren’s — thickened cords or nodules in the palm or fingers, especially the ring and little fingers.
6. Imaging when indicated: Ultrasound for any nodule larger than 2 cm or growing fast; MRI for atypical features or pre-surgical planning.
7. Biopsy only when imaging is atypical or sarcoma cannot be excluded — we avoid biopsy in classic cases because cutting through the nodule can accelerate recurrence.

Imaging: ultrasound and MRI

Ultrasound is the first-line imaging study for plantar fibromatosis — cheap, fast, painless, and excellent at confirming the diagnosis. The classic ultrasound finding is a hypoechoic, fusiform nodule continuous with the plantar fascia. We can measure the nodule precisely and document any vascularity. MRI is reserved for nodules larger than 3–4 cm, rapidly growing nodules, deep nodules, or any case where the clinical picture is atypical. The classic MRI appearance is a low-signal nodule on T1, intermediate on T2, with continuity to the plantar fascia. MRI both confirms the diagnosis and helps surgical planning when intervention is needed.

Observation and watchful waiting

The single most underused treatment for plantar fibromatosis is doing nothing. Many nodules stop growing on their own, never become painful, and require no intervention beyond reassurance. We adopt a watchful-waiting strategy when the nodule is small (under 2 cm), painless, stable, and not interfering with footwear. Patients return every 6–12 months for measurement. The goal is to avoid the surgical morbidity and high recurrence rate of operative treatment in cases that may never have caused trouble.

Orthotics and footwear modifications

The first line of treatment for symptomatic plantar fibromatosis is — perhaps surprisingly — not surgery, not injection, and not radiation. It is a thoughtful orthotic. Our goal is to off-load the nodule so the patient can walk and stand comfortably while we either watch the lump or pursue other treatments.

• Soft accommodative insole with a precise cut-out under the nodule — the gold standard. Custom-molded if the lump is large or multiple.
• Stiff-soled shoe with adequate cushioning — reduces fascia stretch with each step.
• Avoid barefoot walking on hard floors and barefoot exercise (yoga, pilates) until symptomatic.
• Heel-to-toe drop of 6–12 mm — reduces midfoot loading.
• Topical roll-on — we recommend Doctor Hoy’s Natural Pain Relief Gel twice daily over the nodule. As an Amazon Associate (tag biernact-20) we earn from qualifying purchases.
• Off-the-shelf insole option: PowerStep Pinnacle Maxx with a moleskin pad cut-out around the nodule.

Steroid, verapamil, and collagenase injections

Several injection options exist and the choice depends on nodule size, stage, and the patient’s tolerance for off-label care. We discuss each with the patient.

• Corticosteroid injection: Most commonly used; reduces pain by quieting surrounding inflammation. Does not shrink the nodule reliably. Limit to 2–3 per nodule per year.
• Verapamil topical compound: Off-label; some evidence for softening the nodule with months of daily application; minimal side effects.
• Collagenase clostridium histolyticum (Xiaflex): FDA-approved for Dupuytren’s; off-label for plantar disease. Some surgeons use it for early Ledderhose, but the foot data is much weaker than the hand data.
• 5-fluorouracil (5-FU): Used in some centers, particularly Europe, with mixed evidence; usually combined with steroid.

Radiation therapy for early disease

Low-dose radiation therapy is well-established for early Dupuytren’s disease in Europe and is increasingly used for plantar fibromatosis at academic centers in the United States. The protocol typically delivers 30–36 Gy over 5–6 sessions, two courses 6–8 weeks apart. The goal is to halt nodule growth and reduce pain in the active proliferative phase. Long-term studies show good control of disease progression and no significant cancer risk at these doses, but availability is limited and most insurance does not cover it. We offer it as a referral option for patients with painful, progressive, but not yet end-stage disease.

Shockwave and other emerging options

Extracorporeal shockwave therapy (ESWT) has emerging evidence for symptom reduction in plantar fibromatosis, though it does not shrink the nodule. We use it selectively for patients who want a non-injection, non-surgical option and have access to a clinic with the equipment. Other emerging options include cryotherapy (freezing the nodule under ultrasound guidance) and high-intensity focused ultrasound (HIFU); the evidence remains limited but the safety profile is reasonable. Read more about ESWT on our shockwave therapy page.

Surgery: when, what, and the recurrence problem

Surgery for plantar fibromatosis is reserved for patients with disabling pain that has failed conservative care, very large or rapidly growing nodules, or skin tethering that compromises footwear. The procedure has a substantial recurrence rate — this is the single most important counseling point for any patient considering it. We offer several options:

• Local nodule excision: The smallest operation. Recurrence rate 60–100% in published series. We rarely recommend it as a primary procedure.
• Wide local excision: Removal of the nodule plus a margin of normal fascia. Recurrence 25–60%. The standard surgical approach.
• Complete plantar fasciectomy: Removal of the entire plantar fascia from heel to forefoot. Recurrence as low as 8–25%. Larger incision, longer recovery. Best for multifocal disease.
• Subtotal fasciectomy with skin Z-plasty for severe skin tethering.

Recovery from any of these is 6–12 weeks, with non-weight-bearing in a CAM boot for the first 2–4 weeks. The result is excellent in the short term but recurrence, often more aggressive than the original disease, is a real risk — particularly with smaller operations. We tell patients: do not have surgery for a small painless nodule, and if you do have surgery, choose the larger operation in exchange for the lower recurrence rate.

When to see a podiatrist

The most common mistake we see

The most common mistake we see is patients pushing for surgery on a small painless nodule because they want it “gone.” Surgery for plantar fibromatosis carries a recurrence rate that runs from 25% to over 60% depending on the operation, and recurrent disease is often more aggressive than the original. The right move for a small painless nodule is to confirm the diagnosis, fit an accommodative insole, document the size, and watch it. The right move for a painful nodule is to start with conservative care — orthotic, topical, occasional injection — and reserve surgery for the disease that has failed everything else. The patients who do worst are the ones who skip these steps and have a 1-cm nodule excised that returns at 3 cm two years later.

FAQ

Is plantar fibromatosis cancer?

No. Plantar fibromatosis is benign — it does not spread to other parts of the body and does not transform into cancer in the vast majority of cases. The cells are abnormal but not malignant. The key word is “benign locally aggressive” — the lumps can grow and recur but they will not metastasize. The rare exception is a soft-tissue sarcoma that mimics a fibromatosis on early exam, which is why we image any rapidly growing or atypical nodule.

Can plantar fibromatosis go away on its own?

The nodules rarely disappear, but they very often stop growing and stop hurting on their own. Many patients reach a steady state where the lump is present but symptom-free for years or decades. Watching is a legitimate strategy for any small, painless, stable nodule — it is the strategy we recommend for the majority of patients. Asymptomatic disease does not need treatment.

What is the best shoe for plantar fibromatosis?

A stiff-soled shoe with a wide forefoot, moderate cushioning, and a custom or semi-custom insole that has a precise cut-out under the nodule is the gold standard. Brooks Beast, HOKA Bondi, and ASICS Gel-Kayano are common choices. Avoid thin-soled minimalist shoes and barefoot walking on hard floors. Heel-to-toe drop of 6–12 mm is ideal.

Does plantar fibromatosis come back after surgery?

Yes, more often than patients expect. Recurrence rates range from 25% (with complete plantar fasciectomy) to over 60% (with simple nodule excision). Recurrent disease is often more aggressive than the original. This is why we counsel observation and conservative care for as long as possible, and choose the larger operation when surgery is necessary — better one big surgery than three small ones.

Is plantar fibromatosis related to plantar fasciitis?

They both involve the plantar fascia but are different diseases. Plantar fasciitis is inflammation and degeneration of the fascia at its heel insertion. Plantar fibromatosis is benign overgrowth of the fascia in the arch. They can coexist, especially with the orthotic and footwear changes needed for both. We treat them differently: fasciitis with stretching and shockwave, fibromatosis with off-loading and watchful waiting.

Does plantar fibromatosis cause permanent foot deformity?

Unlike Dupuytren’s in the hand, plantar fibromatosis rarely causes contracture deformity in the foot — the foot does not curl into the lump the way a finger can in advanced Dupuytren’s. The disability comes from pressure pain, not from a fixed deformity. This means the disease tends to be more livable than its hand counterpart and patients often manage with conservative care indefinitely.

The bottom line

Plantar fibromatosis (Ledderhose disease) is a benign, slow, and treatable condition. The first job is to confirm the diagnosis with a careful exam and selective imaging. The second job is to off-load the nodule with the right shoe and insole — that alone resolves most symptoms in early disease. Injections, radiation, shockwave, and surgery have roles in specific cases, but most patients do best with patience and accommodation. Surgery should be reserved for disease that has failed conservative care, with the recurrence rate built into the conversation up front. If you have just found a lump in the arch of your foot, a single visit will tell you what it is and what to do about it.

Sources

1. Veith NT, Tschernig T, Histing T, Madry H. Plantar fibromatosis — topical review. Foot Ankle Int. 2013;34(12):1742-1746.
2. Carroll P, Henshaw RM, Garwood C, Raspovic K, Kumar D. Plantar fibromatosis: pathophysiology, surgical and nonsurgical therapies: an evidence-based review. Foot Ankle Spec. 2018;11(2):168-176.
3. Heyd R, Dorn AP, Herkströter M, Rodel C, Mu“ller-Schimpfle M, Fraunholz I. Radiation therapy for early stages of morbus Ledderhose. Strahlenther Onkol. 2010;186(1):24-29.
4. Sammarco GJ, Mangone PG. Classification and treatment of plantar fibromatosis. Foot Ankle Int. 2000;21(7):563-569.
5. de Bree E, Zoetmulder FA, Keus RB, Peterse HL, van Coevorden F. Incidence and treatment of recurrent plantar fibromatosis by surgery and postoperative radiotherapy. Am J Surg. 2004;187(1):33-38.

In-Office Treatment at Balance Foot & Ankle

Reviewed by Dr. Tom Biernacki, DPM, FACFAS

Board-certified foot & ankle surgeon · 3,000+ surgeries · @MichiganFootDoctors (950K+ subscribers)

Last reviewed May 11, 2026 · (810) 206-1402

If home treatment isn’t providing relief for your plantar fibromatosis ledderhose disease arch nodules, our podiatry team at Balance Foot & Ankle can help with same-day evaluations and advanced in-office care.

Dr. Tom Biernacki, DPM

Dr. Tom Biernacki, DPM is a double board-certified podiatrist and foot & ankle surgeon at Balance Foot & Ankle Specialists in Southeast Michigan. With over a decade of clinical experience, he specializes in heel pain, bunions, diabetic foot care, sports injuries, and minimally invasive surgery. Dr. Biernacki is a member of the APMA and ACFAS, and his patient education content on MichiganFootDoctors.com and YouTube has reached over one million views.